

Harvard Bioscience President David Green to Present at Cowen and Company 29th Annual Health Care Conference on March 17, 2009

HOLLISTON, Mass., Mar 10, 2009 (BUSINESS WIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research, today announced that its President, David Green, will present at the Cowen and Company 29th Annual Health Care Conference on March 17, 2009 at 4:40 p.m. EDT at The Boston Marriott Copley Place.

A live webcast and archived replay of the Company's presentation will be available at the "Presentations & Webcasts" tab on our website at www.harvardbioscience.com. Mr. Green's presentation can be downloaded from our website by clicking on the investor presentation icon. The presentation will cover the historical and expected future performance of the business. There will be a question and answer session following the presentation. Some of the information to be presented by Mr. Green or provided in response to questions may contain information that has not previously been disclosed. Additionally, any material financial or other statistical information presented in our presentation or in the question and answer session, which has not been previously disclosed will be archived and available in the Investor Relations section of our website.

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 900 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.

SOURCE: Harvard Bioscience, Inc.

Harvard Bioscience, Inc. David Green, 508-893-8999 President

dgreen@harvardbioscience.com

Fax: 508-429-8478

or

Chane Graziano, CEO

cgraziano@harvardbioscience.com

or

Tom McNaughton, CFO

tmcnaughton@harvardbioscience.com

Disclaimer:

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.